Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Patent metadata

Field	Value
Publication number	US-9360488-B2
Application number	US-201414761591-A
Country	US
Kind code	B2
Filing date	Jan 16, 2014
Priority date	Jan 17, 2013
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.

First claim

We claim:

1. A method for evaluating renal status in a subject, comprising:
determining a measured value for one or more of a urine TIMP2 (Tissue Inhibitor of Metalloproteinase 2) concentration and a urine IGFBP7 (Insulin-Like Growth Factor Binding Protein 7) concentration;
determining a measured value for one or more of a serum creatinine concentration and a urine output;
combining the measured values obtained into a single value to provide an assay result; and
correlating the assay result to the renal status of the subject, wherein said correlation step comprises correlating the assay result(s) to one or more of diagnosis, risk stratification, prognosis, classifying and monitoring of the renal status of the subject.

2. A method according to claim 1 , wherein said correlation step comprises correlating the assay result to prognosis of the renal status of the subject.

3. A method according to claim 1 , wherein said correlating step comprises assigning a likelihood of one or more future changes in renal status to the subject based on the assay result.

4. A method according to claim 3 , wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).

5. A method according to claim 1 , wherein the single value is calculated as urine TIMP2× urine IGFBP7× serum creatinine; urine TIMP2× urine IGFBP7/urine output; urine TIMP2× urine IGFBP7× serum creatinine/urine output; urine TIMP2× serum creatinine; urine TIMP2/urine output; urine TIMP2× serum creatinine/urine output; urine IGFBP7× serum creatinine; urine IGFBP7/urine output; or urine IGFBP7× serum creatinine/urine output.

6. A method according to claim 1 , wherein the correlation step comprises correlating the assay result to a diagnosis of acute renal failure or an injury to renal function.

7. A method according to claim 1 , wherein the correlation step comprises correlating the assay result to a likelihood of a clinical outcome related to a renal injury suffered by the subject.

8. A method according to claim 1 , wherein the correlation step comprises correlating the assay result to a likelihood of one or more future changes in renal status occurring within 30 days of the time at which the body fluid sample is obtained from the subject.

9. A method according to claim 8 , wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.

10. A method according to claim 1 , wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.

11. A method according to claim 1 , wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

12. A method according to claim 1 , wherein said correlating step comprises assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF based on the assay result.

13. A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of an injury to renal function in said subject.

14. A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of reduced renal function in said subject.

15. A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for dialysis in said subject.

16. A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of acute renal failure in said subject.

17. A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal replacement therapy in said subject.

18. A method according to claim 1 , wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal transplantation in said subject.

19. A method according to claim 1 , wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 72 hours of the time at which the body fluid sample is obtained.

20. A method according to claim 1 , wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 48 hours of the time at which the body fluid sample is obtained.

21. A method according to claim 1 , wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 24 hours of the time at which the body fluid sample is obtained.

22. A method according to claim 1 , wherein the subject is in RIFLE stage 0 or R.

23. A method according to claim 22 , wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.

24. A method according to claim 22 , wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.

25. A method according to claim 1 , wherein the subject is not in acute renal failure.

26. A system for evaluating biomarker levels, comprising:
one or more reagents selected from the group consisting of a reagent which specifically binds TIMP2 and a reagent which specifically binds IGFBP7; and
an assay instrument configured to receive a urine sample and contact the one or more reagents with the urine sample and to generate one or more measured values resulting from binding of TIMP2 and/or IGFBP7 to a respective specific binding reagent in the one or more reagents, the measured values indicative of a TIMP2 concentration and/or a IGFBP7 concentration,
wherein the assay instrument is further configured to receive entry of, or determine, one or more measured values for one or more of a serum creatinine concentration and a urine output, and
wherein the assay instrument combines the measured values obtained by the instrument into a single value to provide an assay result.

27. The syste

Assignees

• Astute Medical Inc

Inventors

• Anderberg Joseph
• Gray Jeff
• Mcpherson Paul
• Nakamura Kevin
• Kampf James Patrick

Classifications

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N2333/4703

  Regulators; Modulating activity · CPC title

• G16B40/00

  ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding · CPC title

• G01N2333/4745

  Insulin-like growth factor binding protein · CPC title

• G01N2333/65

  Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2 · CPC title